Sohanya Roshan Cheng net worth and biography

Sohanya Cheng Biography and Net Worth

Chief Commercial Officer and Head of Business Development of Karyopharm Therapeutics

Sohanya Cheng joined Karyopharm in June 2021 and is responsible for leading the company’s Commercial functions including Marketing and New product Planning, Sales, Market Access, and Commercial Operations, as well as Business Development.

Sohanya brings 20 years of experience in biopharmaceutical commercialization and research experience to Karyopharm, with a strong focus on Oncology. Prior to joining Karyopharm, Sohanya served as Vice President, Head of Marketing and Corporate Affairs at Arrowhead Pharmaceuticals. She also spent over a decade at Amgen in various leadership roles, including Executive Director, Head of Marketing & Sales for multiple myeloma and Head of Oncology National Sales, contributing to the commercialization of key oncology brands. She is a member of the board of directors of Carisma Therapeutics Inc.

Sohanya holds an MBA from the MIT Sloan School of Management and both a BSc and MA from the University of Cambridge, UK.

What is Sohanya Roshan Cheng's net worth?: The estimated net worth of Sohanya Roshan Cheng is at least $341.71 thousand as of September 15th, 2025. Ms. Cheng owns 35,856 shares of Karyopharm Therapeutics stock worth more than $341,708 as of July 16th. This net worth evaluation does not reflect any other assets that Ms. Cheng may own. Learn More about Sohanya Roshan Cheng's net worth.
How do I contact Sohanya Roshan Cheng?: The corporate mailing address for Ms. Cheng and other Karyopharm Therapeutics executives is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. Karyopharm Therapeutics can also be reached via phone at (617) 658-0600 and via email at [email protected]. Learn More on Sohanya Roshan Cheng's contact information.
Has Sohanya Roshan Cheng been buying or selling shares of Karyopharm Therapeutics?: Sohanya Roshan Cheng has not been actively trading shares of Karyopharm Therapeutics within the last three months. Most recently, Sohanya Roshan Cheng sold 325 shares of the business's stock in a transaction on Monday, September 15th. The shares were sold at an average price of $6.43, for a transaction totalling $2,089.75. Following the completion of the sale, the executive vice president now directly owns 35,856 shares of the company's stock, valued at $230,554.08. Learn More on Sohanya Roshan Cheng's trading history.
Who are Karyopharm Therapeutics' active insiders?: Karyopharm Therapeutics' insider roster includes Garen Bohlin (Director), Sohanya Cheng (Chief Commercial Officer and Head of Business Development), Michael Kauffman (Director), Michael Mano (Executive Vice President, Chief Legal Officer and Secretary), Michael Mason (CFO), Stephen Mitchener (SVP), Richard Paulson (President and Chief Executive Officer), Reshma Rangwala (Chief Medical Officer & Head of Research), Sharon Shacham (Insider), and Jatin Shah (EVP). Learn More on Karyopharm Therapeutics' active insiders.
Are insiders buying or selling shares of Karyopharm Therapeutics?: During the last twelve months, insiders at the sold shares 12 times. They sold a total of 2,958 shares worth more than $19,037.72. The most recent insider tranaction occured on April, 21st when EVP Reshma Rangwala sold 449 shares worth more than $4,014.06. Insiders at Karyopharm Therapeutics own 1.7% of the company. Learn More about insider trades at Karyopharm Therapeutics.
Information on this page was last updated on 4/21/2026.

Sohanya Roshan Cheng Insider Trading History at Karyopharm Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/15/2025	Sell	325	$6.43	$2,089.75	35,856
9/1/2023	Sell	494	$19.95	$9,855.30	13,605
6/8/2023	Sell	122	$35.25	$4,300.50	14,100
3/1/2023	Sell	749	$45.45	$34,042.05	14,045
6/13/2022	Sell	103	$78.15	$8,049.45	5,996

Sohanya Roshan Cheng Buying and Selling Activity at Karyopharm Therapeutics

Karyopharm Therapeutics Company Overview

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Today's Range

Now: $9.53

$9.38

$9.86

50 Day Range

MA: $9.15

$7.14

$10.67

2 Week Range

Now: $9.53

$3.65

$10.99

Volume

315,583 shs

Average Volume

518,590 shs

Market Capitalization

$215.95 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8